Predictors of XXXX Response to Cetuximab and Panitumumab in 116 @entity1 and a Review of Approaches to Managing Skin Toxicity.

@entity1 @entity1910 @entity470 @entity5 @entity14
INTRODUCTION AND OBJECTIVES: Cetuximab and panitumumab are monoclonal antibodies that target the @entity470 ( @entity470 ) in the treatment of metastatic @entity14 . Most @entity1 develop a @entity1910 , which may predict @entity5 response. We studied whether the other adverse cutaneous effects associated with these monoclonal antibodies are also clinical predictors of response. We also reviewed publications describing approaches to treating the @entity1910 since no evidence-based guidelines have yet been published. MATERIAL AND METHODS: We performed a retrospective study of 116 @entity1 with metastatic @entity14 receiving anti-EGRF therapy with cetuximab or panitumumab at Hospital Universitario Donostia. RESULTS: In total, 81.9% of the @entity1 developed a @entity1910 . @entity1 who received the most cycles of treatment with the @entity470 inhibitor were at the highest risk of developing the @entity1910 , and these @entity1 also had the most severe @entity1910 reactions (P=.03). All of the @entity1 who exhibited a complete @entity5 response had the @entity1910 , and the incidence of @entity1910 was lower in @entity1 with poor @entity5 response (P=.03). We also observed an association between @entity5 response and xerosis (53.4% of the @entity1 who developed xerosis also exhibited @entity5 response, P=.002). The @entity1910 was managed according to an algorithm developed by our department. CONCLUSIONS: Severe @entity1910 and xerosis may be clinical predictors of good response to anti- @entity470 therapy. @entity1 who develop a @entity1910 should be treated promptly because suboptimal treatment of this and other adverse effects can lead to delays in taking the prescribed anti- @entity470 dose or to interruption of therapy.
